NCT01263938View on ClinicalTrials.gov

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
HIV Dementia
Interventions
DRUG

Atorvastatin

"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."

Trial Locations (1)

19104

University of Pennsylvania School of Medicine, Philadelphia

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Pennsylvania

OTHER

NCT01263938 - Modulation of Monocyte Activation by Atorvastatin in HIV Infection | Biotech Hunter | Biotech Hunter